The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
A Clinical Overview of Off-label Use of Gabapentinoid Drugs
Abstract
Background: The gabapentinoid drugs gabapentin and pregabalin were originally developed as antiseizure drugs but now are prescribed mainly for treatment of pain. For gabapentin, the only pain-related indication approved by the US Food and Drug Administration (FDA) is postherpetic neuralgia. For pregabalin, FDA-approved indications related to pain are limited to postherpetic neuralgia, neuropathic pain associated with diabetic neuropathy or spinal cord injury, and fibromyalgia. Despite these limited indications, gabapentin and pregabalin are widely prescribed off-label for various other pain syndromes. Such use is growing, possibly because clinicians are searching increasingly for alternatives to opioids. Observations: This report summarizes the limited published evidence to support off-label gabapentinoid uses, describes clinical cases in which off-label use is problematic, and notes how review articles and guidelines tend to overstate gabapentinoid effectiveness. Conclusions: Clinicians who prescribe gabapentinoids off-label for pain should be aware of the limited evidence and should acknowledge to patients that potential benefits are uncertain for most off-label uses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161
Bril, V., England, J., Franklin, G. M., Backonja, M., Cohen, J., Del Toro, D., Feldman, E., Iverson, D. J., Perkins, B., Russell, J. W., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182166ebe · Cited by 634
Gabapentin for chronic neuropathic pain in adults
Wiffen, P. J., Derry, S., Bell, R. F., Rice, A. S., Tölle, T. R., Phillips, T., & Moore, R. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007938.pub4 · Cited by 561
Arnold, L. M., Russell, I. J., Diri, E. W., Duan, W. R., Young, J. P., Sharma, U., Martin, S. A., Barrett, J. A., & Haig, G. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2008.03.013 · Cited by 277
Trial of pregabalin for acute and chronic sciatica
Mathieson, S., Maher, C. G., McLachlan, A. J., Latimer, J., Koes, B. W., Hancock, M. J., Harris, I., Day, R. O., Billot, L., Pik, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614292 · Cited by 219
The effectiveness of gabapentin in patients with chronic radiculopathy
Yildirim, K., Şışecıoğlu, M., Karatay, S., Erdal, A., Levent, A., Uğur, M., & Şenel, K. (2003) · The Pain Clinic · doi:10.1163/156856903767650718 · Cited by 79
Cited by
Verret, M., Lauzier, F., Zarychanski, R., Perron, C., Savard, X., Pinard, A.-M., Leblanc, G., Cossi, M.-J., Neveu, X., Turgeon, A. F., et al. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003428 · Cited by 457
Löscher, W., & Klein, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00827-8 · Cited by 367
Fibromyalgia: Recent Advances in Diagnosis, Classification, Pharmacotherapy and Alternative Remedies
Maffei, M. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217877 · Cited by 150
Giménez-Campos, M. S., Pimenta-Fermisson-Ramos, P., Díaz-Cambronero, J. I., Carbonell-Sanchís, R., López-Briz, E., & Ruíz-García, V. (2022) · Atención Primaria · doi:10.1016/j.aprim.2021.102144 · Cited by 50
Dranitsaris, G., DeAngelis, C., Pearson, B., McDermott, L., & Pohlmann-Eden, B. (2021) · Applied Health Economics and Health Policy · doi:10.1007/s40258-021-00638-4 · Cited by 10
Metadata
- Authors
- Goodman, C. W., & Brett, A. S.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2019-05-01
- Volume
- 179
- Issue
- 5
- Pages
- 695
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2924513576
- Cited by
- 230
- References
- 6
- FWCI
- 13.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Clinical Overview of Off-label Use of Gabapentinoid Drugs. https://app.cochat.ai/papers/10.1001/jamainternmed.2019.0086
- The paper
- Goodman, C. W., & Brett, A. S. (2019). A Clinical Overview of Off-label Use of Gabapentinoid Drugs. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2019.0086
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.